UNCY — Unicycive Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1766140 ·
Last close
$3.70
Market Cap
$101.35M
52W High
$8.74
52W Low
$3.33
ADV30
1,059,373
Next earnings
2026-11-16

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -8,841,000 -6,997,000 69,933,000 41,966,000 17,309,000
Jun 2026 0 — -10,140,000 -1,722,000 72,029,000 44,185,000 18,759,000
Mar 2026 0 — -8,437,000 -12,823,000 64,406,000 37,371,000 26,702,000
Dec 2025 0 — -7,224,000 -14,668,000 49,135,000 29,198,000 18,938,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-27,839,000
Investing CF
$-17,251,000
Financing CF
$66,948,000
CapEx
$-32,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-1.45
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-142,370,000
Inventory
—
Receivables
—
ST Investments
$17,240,000
EBIT TTM
$-35,182,000
Pretax Income TTM
$-35,224,000
Interest Exp TTM
$42,000
Analysts
10

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -29,517,000 -26,555,000 49,135,000 18,938,000 30,197,000 -31,317,000
Dec 2024 0 -32,117,000 -36,729,000 31,668,000 24,237,000 7,431,000 -28,575,000
Dec 2023 675,000 -20,774,000 -30,544,000 14,191,000 18,000,000 -3,809,000 -18,283,000
Dec 2022 951,000 -18,052,000 -18,058,000 2,818,000 3,284,000 -466,000 -15,651,000

TTM Snapshot

Revenues TTM
$1,466,000
NetIncome TTM
$-35,223,000
OpCashFlow TTM
—
Assets (Latest)
$72,029,000
Forward EPS
$1.66

Max Pain — expiry 2028-01-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $3.57 · call volume: 205 · put volume: 2
Expected Move to 2028-01-21: ±$3.15 (88.24%) — implied range $0.42 – $6.72 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
OGI ORGANIGRAM GLOBAL INC. $101.90M $0.71 —
IMUX IMMUNIC, INC. $100.01M $7.33 —
EQ Equillium, Inc. $99.61M $1.21 —
NERV Minerva Neurosciences, Inc. $103.13M $2.16 —
ADAG Adagene Inc. $99.37M $1.48 —

News headlines (Yahoo Finance, 1h cache)

Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
2026-11-17 09:09 · Yahoo
Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-04 23:06 · Yahoo
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission, PDUFA Date of March 25, 2027
2026-10-21 21:35 · Yahoo
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027
2026-10-21 11:05 · Yahoo
Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-10-13 12:35 · Yahoo
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
2026-10-01 11:05 · Yahoo
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
2026-09-29 11:05 · Yahoo
Unicycive Therapeutics shares rise after second-quarter loss beats forecasts
2026-08-12 12:00 · Yahoo
Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies
2026-07-01 22:13 · Yahoo
Unicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY)
2026-06-30 12:42 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.